

Method for screening of extracellular tissue peptides in mammalian tissue samples for health status evaluation, disease diagnostics and neoantigen discovery

About technology

Method for screening of extracellular tissue peptides in mammalian tissue samples for health status evaluation, disease diagnostics and neoantigen discovery

invention refers to an extracellular and peptidomics major histocompatibility complex (MHC) class I immunopeptidomics sample preparation, qualitative and quantitative method from the solid tumors by antibody-free approach. The extracellular peptidomics and immunopeptidomics from solid tumors based on amino acid sequencing with tandem mass spectrometry. The invention is simple, costeffective, fast, and comprehensive for solid tumor peptidomics profiling. Moreover, the methods enable the discovery of complex extracellular peptidomics that can be used for health status evaluation, disease diagnostics, and prognosis. class I immunopeptidomics MHC neoantigen discovery, vaccine development/the design of immunotherapies. Hence inventions provide valuable insights for understating the applied biological questions. basic and Neoantigen is the peptide presented by cancerspecific MHC class I (or II) molecules. The invention enable to successfully screening of MHC class I immunopeptides/peptides from the tissue. Therefore, all MHC class I peptides can be used for neoantigen discovery amongst MHC class I immunopeptides/peptides that specific to the cancer cell and able to induce the immune response to kill the cancer cell.



Research Team:

PhD Sachin Kote Prof. Natalia Marek-Trzonkowska PhD Artur Piróg PhD Jakub Faktor Prof. UG, dr hab. Paulina Czaplewska

IP protection

The invention is the subject of a European patent application EP23182549.8 and PCT/EP2023/081235.

Implementation progress

TRL 4 –Technology validated in laboratory conditions

Cooperation opportunities

- Licensing agreement
- Transfer of ownership
- Spin off

